Cabergoline hyperprolactinemia

Dopamine agonists suppress prolactin release very effectively in patients with hyperprolactinemia. GH release is reduced in patients with acromegaly, although not as effectively. Cabergoline and bromocriptine are also used in Parkinson s disease to improve motor function and reduce levodopa requirements (see Chapter 28). Newer, nonergot D2 agonists... 

Results from a clinical trial of cabergoline in women with hyperprolactinemia and anovulation. A The dotted line indicates the upper limit of normal serum prolactin concentrations. B Complete success was defined as pregnancy or at least two consecutive menses with evidence of ovulation at least once. Partial success was two menstrual cycles without evidence of ovulation or just one ovulatory cycle. The most common reasons for withdrawal from the trial were nausea, headache, dizziness, abdominal pain, and fatigue. 

Five patients (four women and one man, aged 30-45 years), who were evaluated for risperidone-induced hyperprolactinemia, had significant hyperprolactinemia, with prolactin concentrations of 66-209 pig/1 (1017). All but one had manifestations of hypogonadism, and in these four patients, risperidone was continued and a dopamine receptor agonist (bromocriptine or cabergoline) was added in three patients this reduced the prolactin concentration and alleviated the hypogonadism. 

Tollin SR. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Invest 2000 23(ll) 765-70. 

Cabergoline Therapy of hyperprolactinemia Oral tablet Proved to be effective and safe, without adverse effects of oral administration 331... 

Cabergoline is an ergoline derivative that has been used in patients with hyperprolactinemia (SEDA-15,133), but is used nowadays in patients with Parkinson s disease. Its adverse effects include nausea, hjrpotension, headache. 

Cabergoline is a selective D2 ergot agonist with a long half-life (70 hours) that is as effective as bromocriptine but dosed up to 4 mg once a day. It is available in the United States only as a 0.5-mg tablet (Dostinex, Pharmacia) for the treatment of hyperprolactinemia. A transdermal delivery form of the potent dopaminergic agonist... 

Cabergoline is commercially available as 0.5-mg oral tablets. The initial dose of cabergoline for the treatment of hyperprolactinemia is 0.5 mg once weekly or in divided doses twice weekly. This dose may be increased by increments of 0.5 mg at 4-week intervals based on serum prolactin concentrations. The usual dose is 1 to 2 mg weekly however, doses as high as 4.5 mg weekly have been used. Recent studies have also evaluated the efficacy of a vaginal dosage form of cabergoline to reduce the adverse effects associated with oral therapy. ... 

Cabergoline and bromocriptine. These agents are used in the therapy of hyperprolactinemia. 

Differentiate between cabergoline and bromocriptine in the therapy of hyperprolactinemias. 

F. Prolactin-Inhibiting Hormone (PIH, Dopamine) Dopamine is the physiologic inhibitor of prolactin release. Because of its peripheral effects and the need for parenteral administration, dopamine is not useful in the control of hyperprolactinemia, but bromocriptine and other orally active ergot derivatives (eg, cabergoline. pergolide) are effective in reducing prolactin secretion from the normal gland as well as from pituitary tumors. 

Another example of a negative study has been published [70 ]. In a cross-sectional, two-dimensional echocardiographic study in 72 patients (median age 36 years, 19 men) who took cabergohne for hyperprolactinemia and 72 controls prospectively matched for age, sex, and cardiovascular risk factors, there was no association between cabergoline treatment and valvulopathy the median cumulative dose exposure was 126 (58-258) mg. 

Colao A, Di SA, Guerra E, De LM, Mentone A, Lombardi G (2006) Drag insight cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women. Nat Clin Pract Endocrinol Metab 2 200-210... 

---